PRLD
Company Description
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.14M | 7.00M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (99.50M) | (127.17M) | (121.83M) | (115.44M) | (111.69M) | (56.93M) | (27.57M) | (14.68M) |
| EPS | -1.29 | -1.68 | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -9.31 |
| Free Cash Flow | (56.37M) | (103.65M) | (110.58M) | (86.75M) | (85.85M) | (46.80M) | (26.45M) | (13.48M) |
| FCF / Share | -0.73 | -1.37 | -1.83 | -1.83 | -1.80 | -1.07 | -0.82 | -8.56 |
| Operating CF | (56.30M) | (102.89M) | (107.06M) | (83.73M) | (83.53M) | (46.18M) | (25.66M) | (12.95M) |
| Total Assets | 141.31M | 175.51M | 277.67M | 220.50M | 305.10M | 223.59M | 21.87M | 16.41M |
| Total Debt | 17.79M | 18.02M | 16.89M | 1.83M | 1.74M | 0 | 258,000 | 0 |
| Cash & Equiv | 35.26M | 12.47M | 25.29M | 30.61M | 31.83M | 218.31M | 18.88M | 15.60M |
| Book Value | 68.64M | 131.46M | 237.09M | 195.44M | 285.90M | 212.18M | (49.41M) | (22.69M) |
| Return on Equity | -1.45 | -0.97 | -0.51 | -0.59 | -0.39 | -0.27 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.58M | 5.64M | 6.50M | 0 | 0 | 4.00M | 3.00M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.38M) | (16.46M) | (19.73M) | (31.23M) | (32.09M) | (28.73M) | (32.27M) | (34.74M) | (31.43M) | (33.08M) | (30.61M) | (30.43M) |
| EPS | -0.13 | -0.26 | -0.26 | -0.41 | -0.42 | -0.38 | -0.43 | -0.46 | -0.42 | -0.48 | -0.45 | -0.54 |
| Free Cash Flow | (21.68M) | 23.12M | (19.11M) | (26.09M) | (34.28M) | (20.80M) | (27.36M) | (23.42M) | (32.08M) | (24.71M) | (26.27M) | (28.65M) |
| FCF / Share | -0.26 | 0.37 | -0.25 | -0.34 | -0.45 | -0.27 | -0.36 | -0.31 | -0.42 | -0.36 | -0.39 | -0.51 |
| Operating CF | (21.68M) | 23.12M | (19.11M) | (26.07M) | (34.23M) | (20.74M) | (27.30M) | (23.06M) | (31.79M) | (23.58M) | (25.68M) | (27.67M) |
| Total Assets | 119.64M | 141.31M | 94.75M | 114.92M | 141.26M | 175.51M | 197.22M | 224.29M | 247.11M | 277.67M | 258.51M | 280.61M |
| Total Debt | 17.72M | 17.79M | 17.85M | 17.92M | 17.92M | 18.02M | 18.14M | 18.20M | 17.64M | 16.89M | 475,000 | 938,000 |
| Cash & Equiv | 21.76M | 35.26M | 47.53M | 25.75M | 40.27M | 12.47M | 11.13M | 27.83M | 24.71M | 25.29M | 15.90M | 26.45M |
| Book Value | 60.18M | 68.64M | 58.53M | 75.84M | 103.18M | 131.46M | 156.43M | 182.28M | 210.73M | 237.09M | 238.26M | 262.06M |
| Return on Equity | -0.17 | -0.24 | -0.34 | -0.41 | -0.31 | -0.22 | -0.21 | -0.19 | -0.15 | -0.14 | -0.13 | -0.12 |
